

- range 50 to 97 years). Additional information on the procedures is available as supplemental material (12).
3. D. Blacker *et al.*, *Neurology* **48**, 139 (1997).
 4. P. Kehoe *et al.*, *Hum. Mol. Genet.* **8**, 237 (1999).
 5. A. J. Myers *et al.*, *Neurobiol. Aging* **21** (suppl.), S103 (2000).
 6. R. W. Cottingham Jr., R. M. Idury, A. A. Schaffer, *Am. J. Hum. Genet.* **53**, 252 (1993).
 7. A. A. Schaffer, S. K. Gupta, K. Shriram, R. W. Cottingham Jr., *Hum. Hered.* **44**, 225 (1994).
 8. L. Kruglyak, M. J. Daly, M. P. Reeve-Daly, E. S. Lander, *Am. J. Hum. Genet.* **58**, 1347 (1996).
 9. A. Kong, N. J. Cox, *Am. J. Hum. Genet.* **61**, 1179 (1997).
 10. Version 1.0, applying the exponential model.
 11. Disease gene frequencies were set to 0.01 in the dominant model and to 0.05 in the recessive model. Penetrance in affected individuals corresponded to phenocopy rates of 5% for definite AD ($n = 278$), 10% for probable AD ($n = 645$), and 14% for possible AD ($n = 65$). Families were classified as "late-onset" when all sampled affected individuals had onset ages ≥ 65 years,

- as "APOE $\epsilon 4/\epsilon 4$ -positive" if at least one affected individual had the $\epsilon 4/\epsilon 4$ genotype, and as "APOE $\epsilon 4/\epsilon 4$ -negative" otherwise. Parametric analyses were performed on affected individuals only.
12. Supplementary data are available at Science Online at www.sciencemag.org/cgi/content/full/290/5500/2302/DC1.
 13. Intermarker distances are according to marker locations from Marshfield, except for interval D10S566 to D10S1671, where 0.7 cM was used according to the MAP-O-MAT program (http://linkage.rockefeller.edu/1802/mapomat/mapomat_menu.html).
 14. The list of individuals included in Myers *et al.* (5) was supplied by P. Holmans.
 15. GenBank accession number AL356128.
 16. D. Rabinowitz, N. Laird, *Hum. Hered.* **50**, 211 (2000).
 17. Analyses are based on estimated empirical variances (to account for the presence of linkage) (20) as implemented in FBAT (version 1.0, 1999) under an additive disease model.
 18. S. B. Roberts, C. J. MacLean, M. C. Neale, L. J. Eaves, K. S. Kendler, *Am. J. Hum. Genet.* **65**, 876 (1999).

19. E. R. Hauser, M. Boehnke, *Am. J. Hum. Genet.* **61**, A278 (1997).
20. S. L. Lake, D. Blacker, N. M. Laird, *Am. J. Hum. Genet.* **67**, 1515 (2000).
21. We thank T. Moscarillo for analytical assistance. We thank all families for their participation and the staff at NIMH and at all three sites for assistance with all aspects of the project. The NIMH study involves three research teams in collaboration with NIMH extramural staff. The principal investigators (PIs) and co-PIs at each site are as follows: Massachusetts General Hospital: M. S. Albert, R.E.T., and D.B.; Johns Hopkins University: S. Bassett, G. A. Chase, and M. F. Folstein; and the University of Alabama: R.C.P.G. and L. E. Harrell. This work was sponsored by grants from the NIMH and National Institute on Aging (NIA) (Alzheimer's Disease Research Center). L.B. is a fellow of the Deutsche Forschungsgemeinschaft. A.J.S. is an NIA-National Research Service Awards recipient.

31 August 2000; accepted 16 November 2000

Linkage of Plasma A β 42 to a Quantitative Locus on Chromosome 10 in Late-Onset Alzheimer's Disease Pedigrees

Nilufer Ertekin-Taner,¹ Neill Graff-Radford,¹ Linda H. Younkin,¹ Christopher Eckman,¹ Matthew Baker,¹ Jennifer Adamson,¹ James Ronald,¹ John Blangero,² Michael Hutton,^{1*} Steven G. Younkin¹

Plasma A β 42 (amyloid β 42 peptide) is invariably elevated in early-onset familial Alzheimer's disease (AD), and it is also increased in the first-degree relatives of patients with typical late-onset AD (LOAD). To detect LOAD loci that increase A β 42, we used plasma A β 42 as a surrogate trait and performed linkage analysis on extended AD pedigrees identified through a LOAD patient with extremely high plasma A β . Here, we report linkage to chromosome 10 with a maximal lod score of 3.93 at 81 centimorgans close to D10S1225. Remarkably, linkage to the same region was obtained independently in a genome-wide screen of LOAD sibling pairs. These results provide strong evidence for a novel LOAD locus on chromosome 10 that acts to increase A β .

The autosomal dominant mutations that cause early-onset familial AD all increase A β 42 in plasma and brain (1–6). Compared to age-matched controls, plasma A β 42 is also elevated in the cognitively normal first-degree relatives and extended families of patients with typical LOAD (7). To assess the genetic component affecting plasma A β 42 levels, we collected 10 LOAD pedigrees [see Web table 1 for family description and ascertainment scheme (8)], used a sandwich enzyme-linked immunosorbent assay (5) to measure plasma A β 42, estimated the heritability of plasma

A β 42 using the variance component method implemented in SOLAR (9), and found it to be $64.8 \pm 15.5\%$ ($P < 0.0001$; $n = 203$).

Given the association of elevated plasma A β 42 with AD, the substantial heritability of this quantitative trait in our LOAD pedigrees, and the recent successful linkage of genetic loci to quantitative traits associated with complex diseases (10–12), we decided to search for LOAD genes by performing linkage analysis in our LOAD families using plasma A β 42 as a surrogate trait. Using a traditional affected sibling pair approach, Kehoe *et al.* (13) performed a genome-wide screen for LOAD loci that identified regions on chromosomes 1, 5, 9, 10, and 19 with multipoint lod (logarithm of odds for "linkage/no linkage") scores (MLSS) > 1 . Reasoning that these regions

might contain genes linked to AD because they elevate A β 42, we tested each region for linkage to plasma A β 42.

In previous searches for genes governing quantitative traits, the power to identify gene(s) with strong effect (major genes) has been increased by performing linkage analysis on families ascertained using probands with extreme values for the quantitative trait in question (10, 12). For this reason, we focused our analysis on five families that had an AD proband with extremely high plasma A β (top 10% of AD patients). When robust MLSSs for these five families were calculated using SOLAR (9, 14), the region on chromosome 10 gave a maximum MLS of 3.93 (Fig. 1) at 81 centimorgans (cM) between D10S1227 and D10S1211 (empirical P value by simulation = 0.0001). In all other regions, which were tested both in the extreme families and the entire group, the maximum MLS was < 0.5 [see Web tables 2 and 3 for details of the analysis (8)]. Because we examined only 10 families and deliberately weighted our collection with pedigrees ascertained via an AD proband with high A β (top 10%), our results [Web tables 2 and 3 (8)] cannot be used to evaluate the contribution of the chromosome 10 locus to AD in general.

Here, we focused on A β 42 because of its close association with AD, but we also performed linkage analysis on the five "extreme" families using plasma A β 40 as the quantitative trait. In this analysis, the maximum MLS obtained for the chromosome 10 region was 1.36 (point-wise P value ~ 0.006). All other regions gave maximum MLSSs < 0.3 . This result suggests that the locus on chromosome 10 may influence both A β 40 and A β 42.

There are no obvious candidate genes in the chromosome 10 region that we identified (1-lod support interval of ~ 8 cM), but the gene for insulin-degrading enzyme (IDE), which is 30 cM distal to our peak, is considered by Bertram *et al.* in their accompanying

¹Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA.

²Southwest Foundation for Biomedical Research, San Antonio, TX 78245, USA.

*To whom correspondence should be addressed. E-mail: hutton.michael@mayo.edu




Fig. 1. Chromosome 10 multipoint plot. Robust multipoint lod scores on chromosome 10 were calculated for the five LOAD families that had an AD proband with extremely high plasma A β . The markers that were genotyped are shown below the plot. A maximum MLS of 3.93 is at 81 cM between D10S1227 and D10S1211.

report (15, 16).

The results we report show that plasma A β can be used as a quantitative trait for identifying novel LOAD loci. This approach is a powerful complement to other methods for identifying genetic risk factors for LOAD. It enables the evaluation of candidate genes at a mechanistic level and, because multiple generations can be analyzed in extended pedigrees grouped according to their phenotypic characteristics, the power to detect linkage and to obtain precise localization is increased. Thus, by analyzing 124 subjects in five families identified via a proband with extremely high A β 42, we obtained highly significant linkage that was well localized to chromosome 10 with a 1-lod support interval of ~8 cM. These results fit well with those obtained in the second stage of the sibling pair study that provided our candidate regions (17). In that study, published jointly with our findings, Myers *et al.* analyzed 429 affected sibling pairs in 342 sibships and obtained significant linkage to the same region of chromosome 10 with a 1-lod support interval of ~16 cM. Together, the results of these two studies, performed on nonoverlapping family series, provide compelling, mutually confirmatory evidence for a novel LOAD locus on chromosome 10. From our results, it appears that this locus increases risk for AD by increasing A β . Because we have sought linkage to the high A β phenotype in only a small fraction of the human genome, it is likely that additional LOAD loci will be detected by this method as we evaluate the remainder of the genome in our collection of families.

References and Notes

1. M. Citron *et al.*, *Nature* **360**, 672 (1992).
2. X.-D. Cai, T. E. Golde, S. G. Younkin, *Science* **259**, 514 (1993).
3. N. Suzuki *et al.*, *Science* **264**, 1336 (1994).
4. D. R. Borchelt *et al.*, *Neuron* **17**, 1005 (1996).
5. D. Scheuner *et al.*, *Nature Med.* **2**, 864 (1996).
6. K. Duff *et al.*, *Nature* **383**, 710 (1996).
7. S. G. Younkin, *Neurobiol. Aging* **21** (15), S136 (abstract 612) (2000).
8. Web tables are available at www.sciencemag.org/cgi/content/full/290/5500/2303/DC1.
9. L. Almasy, J. Blangero, *Am. J. Hum. Genet.* **62**, 1198 (1998).
10. L. R. Cardon *et al.*, *Science* **266**, 276 (1994).
11. A. G. Comuzzie *et al.*, *Nature Genet.* **15**, 273 (1997).
12. K. Clement *et al.*, *Diabetes* **45**, 687 (1996).
13. P. Kehoe *et al.*, *Hum. Mol. Genet.* **8**, 237 (1999).
14. J. Blangero, J. T. Williams, L. Almasy, *Genet. Epidemiol.* **19S1**, S8 (2000).
15. IDE is an interesting candidate, because there are several reports linking A β degradation with IDE activity, but this gene is 30 cM distal to the peak identified by our linkage analysis. We have, moreover, found no potential pathogenic variants by sequencing 90% of the IDE coding region in 11 members from our collection of pedigrees.
16. L. Bertram *et al.*, *Science* **290**, 2302 (2000).
17. A. Myers *et al.*, *Science* **290**, 2304 (2000).
18. We thank C. E. Billings, E. E. Croston, L. A. Crump, R. M. Fletcher, E. C. Jobli, R. L. Lawson, L. M. Makarov, J. G. Pagdanganan, and F. C. Parfitt for the family collections; F. T. Pishotta, T. Dyer, and C. Peterson for expert technical assistance with computing; and the LOAD families for their support and participation. Supported by a grant from Clarice and Robert Smith, Alzheimer Disease Research Center grant P50 AG16574, National Institute on Aging grant AG06656, and NIH grant MH59490 (J.B.).

31 August 2000; accepted 16 November 2000

Susceptibility Locus for Alzheimer's Disease on Chromosome 10

Amanda Myers,¹ Peter Holmans,^{1*} Helen Marshall,¹ Jennifer Kwon,¹ David Meyer,¹ Dzanan Ramic,¹ Shantia Shears,¹ Jeremy Booth,¹ Fabienne Wavrant DeVrieze,² Richard Crook,² Marian Hamshere,³ Richard Abraham,³ Nigel Tunstall,⁴ Francis Rice,³ Stephanie Carty,³ Sara Lillystone,³ Pat Kehoe,³ Varuni Rudrasingham,³ Lesley Jones,³ Simon Lovestone,⁴ Jordi Perez-Tur,⁵ Julie Williams,³ Michael J. Owen,³ John Hardy,² Alison M. Goate^{1†}

The apolipoprotein E (*APOE*) gene is the only genetic risk factor that has so far been linked to risk for late-onset Alzheimer's disease (LOAD). However, 50 percent of Alzheimer's disease cases do not carry an *APOE4* allele, suggesting that other risk factors must exist. We performed a two-stage genome-wide screen in sibling pairs with LOAD to detect other susceptibility loci. Here we report evidence for an Alzheimer's disease locus on chromosome 10. Our stage one multipoint lod score (logarithm of the odds ratio for linkage/no linkage) of 2.48 (266 sibling pairs) increased to 3.83 in stage 2 (429 sibling pairs) close to D10S1225 (79 centimorgans). This locus modifies risk for Alzheimer's disease independent of *APOE* genotype.

Mutations in three genes encoding β -amyloid precursor protein (APP), presenilin 1, and presenilin 2 cause the rare, early-onset autosomal dominant form of Alzheimer's disease (AD) (1). These mutations all affect APP metabolism such that more A β 42 peptide is

produced (2). In contrast, most AD cases have ages of onset above 65 years and exhibit no clear pattern of inheritance (late-onset Alzheimer's disease or LOAD). The E4 allele of the apolipoprotein E (*APOE*) gene is the only known genetic risk factor for LOAD (3, 4). However, 50% of LOAD cases carry no *APOE4* alleles, indicating that there must be additional risk factors (4).

To look for other susceptibility loci, we performed a two-stage genome-wide screen in affected Caucasian sibling pairs (ASPs). Each sibling used for analysis had an age of onset ≥ 65 years and a diagnosis of definite or probable AD. If there were more than two affected siblings within a family, all siblings were sampled and genotyped. In stage 1, 292 ASPs were genotyped with markers spaced about 20 centimorgans (cM) apart throughout

¹Department of Psychiatry, Washington University School of Medicine, 660 S. Euclid, St. Louis, MO 63110, USA. ²Laboratory for Neurogenetics, Birdsall Building, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA. ³Department of Psychological Medicine, University of Wales College of Medicine, Cardiff, UK. ⁴Institute of Psychiatry, De Crespigny Park, Denmark Hill, London SE58AF, UK. ⁵Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, E-46010 València, Spain.

*Present address: MRC Biostatistics Unit, Institute of Public Health, Cambridge CB2 2SR, UK.

†To whom correspondence should be addressed. E-mail: goate@icarus.wustl.edu